血管发生也可以导致像癌症这样的疾病，新生的血管滋养肿瘤生长。
Blood vessel formation can also contribute to disease in Settings like cancer, where vessels feed a growing tumor.
新生血管是肿瘤生长和转移的基础。
血管内皮细胞生长因子(VEGF)及其受体在肿瘤血管新生中起重要作用，阻断VEGF的生成已成为抗肿瘤治疗的新靶点。
Vascular endothelial growth factor (VEGF) and its receptor play a critical role in tumor-associated angiogenesis and have become the new targets of anti-tumor therapy.
本文分析了68例原发性肺癌和2例肺转移癌病例的支气管动脉造影（BAG）中重要征象之一的肿瘤内新生血管。
The neovascularity within the tumor, one of the important signs of bronchial arteriography (BAG) in 68 cases with primary bronchogenic carcinoma and 2 cases with metastatic tumors was analysed.
血管内皮细胞生长因子及其受体在肿瘤新生血管形成中起重要作用，成为肿瘤治疗的新靶点。
Vascular endothelial growth factor (VEGF) and its receptor play a critical role in tumor associated angiogenesis and has become the new targets of anti tumor therapy.
近年研究表明，在肿瘤组织中，TF常表达于肿瘤细胞及肿瘤新生血管内皮细胞，提示其与肿瘤生长、肿瘤新生血管的形成密切相关。
Recent researches have found that TF always exists in tumor cells and neovascular endothelial cells, suggesting that TF is closely related to the growth of tumor and neovascular epithelial cells.
新生血管的形成是肿瘤生长和转移表达肿瘤生物学特征的基础。
New vessels is the base of the growth and metastasis of tumor.
血管发生是癌组织得以生存的决定性过程，因为如果肿瘤周围没有新生血管供给营养，癌细胞就会营养缺乏和死亡。
Angiogenesis is a process crucial for cancer sustainability since without new blood vessels around the tumour site to supply nutrients, cancerous cells will starve and die.
血管瘤：一种新生血管构成的先天性良性皮肤肿瘤。
Hemangioma: Congenital Benign tumour made of Blood vessels in the skin.
新生血管生成在肿瘤的发生和生长过程中是一个至关重要的事件。
Angiogenesis is one of the crucial events for cancer development and growth.
结论CD 105是一种较CD34更好的肿瘤性血管内皮细胞标记物，适用于肿瘤新生血管的研究。
ConclusionCD105 is more suitable than CD34 in studying the newborn blood vessels of malignant tumor.
其活性对维持肿瘤细胞的能量代谢、新生血管形成以及促进肿瘤的增殖生长、侵袭和转移起着重要作用。
Its activity plays important roles in maintaining the energy metabolism of tumor cells, in the new angiogenesis and in promoting the tumor's multiplication, invasion and metastasis.
肿瘤的生长和转移依赖于肿瘤血管新生。
Growth and metastasis of tumors are dependent on neovascularization.
新生血管大量形成在实体瘤的生长和转移中起着关键的作用。血管内皮生长因子(VEGF)是介导肿瘤血管生成的最主要因素。
New vessel formation plays a key role in tumor growth and transforming, and the Vascular endothelial growth factor (VEGF) is the most important factor inducing tumor vessel formation.
结论CD 105可以作为新生血管的标记物用于抗肿瘤血管形成的研究和治疗。
ConclusionCD105 may be used as a new marker of neovascularization in the research and treatment of anti-tumor angiogenesis.
目前认为肿瘤的增殖和转移依赖于血管新生。
Now it is known that the tumor proliferation and metastasis depend on angiogenesis.
FISH和免疫荧光染色证实骨髓源性的MSC可以参与小鼠肿瘤新生血管形成。
FISH and immunofluorescence staining showed that the myelogenic MSC could take part in the tumor neovascularity.
实验证实，将RI注射到小鼠的移植肿瘤组织内，导致实体肿瘤组织大面积坏死及新生血管明显减少。
The experiments had shown that inoculating ri into the transplanted tumor of mouse resulted in significant reduction of the amount of neovascular and massive necrosis of tumor cells.
VEGF也是胚胎发育、软骨内骨形成、女性生殖系统、以及肿瘤和眼球内血管新生所必需的。
VEGF is essential for embryonic development, endochondral bone formation, female reproductive functions. Substantial evidence also implicates VEGF in tumor and intraocular angiogenesis.
CD34高表达是新生血管形成活跃的表现，说明肿瘤组织的高增殖性；
The higher expression of CD34 showed active angiogenesis, indicating higher proliferation of tumor tissue.
VEGF及其受体介导的肿瘤血管新生在肿瘤的生长和转移中具有重要的作用。
Angiogenesis induced by VEGF and its receptor (VEGFR) play a critical role in tumor growth and metastasis.
肿瘤细胞释放可溶性的促血管生成因子诱导新生血管生成。
Tumor cells release soluble angiogenic factors inducing neovascularization, a process referred to as the "angiogenic switch".
天门冬酰胺酰甘氨酰精氨酸(NGR)是特异性地定位于肿瘤新生血管受体的多肽基序，在肿瘤诊断和治疗方面具有潜在的应用前景。
The NGR peptide is a ligand specifically binding to tumor angiogenic blood vessels, and thus has potential usage in the diagnosis and therapy of tumor.
血管生成促进因子和血管生成抑制因子的平衡控制着肿瘤新生血管的形成。
Formation of tumor new vessels is controlled by balances between angiogenic stimulators and inhibitors.
抑制肿瘤新生血管的生成有望降低甚或遏制对非小细胞肺癌化疗的耐药性。
Inhibition of angiogenesis in tumor is expected to reduce or inhibit drug resistance to NSCLC.
抑制肿瘤新生血管的生成有望降低甚或遏制对非小细胞肺癌化疗的耐药性。
Inhibition of angiogenesis in tumor is expected to reduce or inhibit drug resistance to NSCLC.
应用推荐